Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

PHASE3TerminatedINTERVENTIONAL
Enrollment

1,065

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

July 19, 2022

Study Completion Date

March 24, 2023

Conditions
Covid19
Interventions
BIOLOGICAL

sotrovimab

Sotrovimab 500 mg given by intravenous infusion over 15 min

BIOLOGICAL

sotrovimab

Sotrovimab 500 mg given by intramuscular injection

BIOLOGICAL

sotrovimab

Sotrovimab 250 mg given by intramuscular injection

BIOLOGICAL

sotrovimab

Sotrovimab 2000 mg given by intravenous infusion over 60 min

BIOLOGICAL

Sotrovimab

Sotrovimab 2000 mg given by intravenous infusion over 30 min

BIOLOGICAL

Sotrovimab

Sotrovimab 2000 mg given by intravenous infusion over 15 min

BIOLOGICAL

Sotrovimab

Sotrovimab up to 3000 mg given by intravenous infusion over 90 min

Trial Locations (50)

10456

Investigative Site, The Bronx

15478

Investigative Site, Smithfield

27030

Investigative Site, Mount Airy

27262

Investigative Site, High Point

30318

Investigative Site, Atlanta

32174

Investigative Site, Ormond Beach

32607

Investigative Site, Gainesville

33012

Investigative Site, Hialeah

33013

Investigative Site, Hialeah

33016

Investigative Site, Hialeah

33024

Investigative Sites, Pembroke Pines

33032

Investigative Site, Miami

33064

Investigative Site, Pompano Beach

33125

Investigative Site, Miami

33126

Investigative Site, Doral

Investigative Site, Miami

33135

Investigative Site, Miami

33144

Investigative Site, Miami

33155

Investigative Site, Miami

33157

Investigative Site, Palmetto Bay

33166

Investigative Site, Doral

33169

Investigative Site, North Miami Beach

33175

Investigative Site, Miami

33176

Investigative Site, Miami

33180

Investigative Site, Miami

33614

Investigative Site, Tampa

33615

Investigative Site, Tampa

34208

Investigative Site, Bradenton

36207

Investigative Site, Anniston

43215

Investigative Site, Columbus

46544

Investigative Site, Mishawaka

48126

Investigative Site, Sterling Heights

75126

Investigative Site, Forney

75149

Investigative Site, Mesquite

77017

Investigative Site, Houston

77024

Investigative Site, Houston

77090

Investigative Site, Houston

77521

Investigative Site, Baytown

78041

Investigative Site, Laredo

78577

Investigative Site, Pharr

83404

Investigative Site, Idaho Falls

85210

Investigative Site, Mesa

85712

Investigative Site, Tucson

87042

Investigative Site, Limoges

89113

Investigative Site, Las Vegas

90017

Investigative Site, Los Angeles

90274

Investigative Site, Rolling Hills Estates

98034

Investigative Site, Kirkland

98109

Investigative Site, Seattle

02000

Investigative Site, Kyiv

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Vir Biotechnology, Inc.

INDUSTRY

NCT04913675 - Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | Biotech Hunter | Biotech Hunter